CNBC Adaptive Biotechnologies went public on Thursday, jumping 95% above its offer price at the open. That marked the best post-IPO pop of the year for any company, on an offer-to-open basis. The Seattle-based biotech, which provides tests used to diagnose and treat diseases, began trading shortly after noon Eastern Time under the ticker symbol […]